This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing Gilead’s Trodelvy in Metastatic Breast Cancer in anticipation of Phase 3 Data

Ticker(s): GILD

Who's the expert?

Institution: University of Cambridge

  • Clinical Senior Research Associate and Academic Consultant in Breast Cancer Therapeutics at the University of Cambridge.
  • Currently manages 30 patients with HR+/HER- breast cancer each month.
  • Focus on Early phase breast cancer clinical trials with expertise in first-in-human studies & drug combination trials, new small molecule & antibody therapeutics and the development of pharmacodynamic and predictive biomarkers.

Interview Questions
Q1.

Please tell us about your clinical experience. How many patients with HR+/HER2- MBC do you see on a yearly basis? What’s the chemotherapy choices available and what do you see the best results with?

Added By: slingshot_insights
Q2.

What are the pros and cons of SN-38, the topoisomerase I inhibitor chemotherapy part of Trodelvy, considering it isn't a targeted medicine, which means it can affect healthy cells as well?

Added By: slingshot_insights
Q3.

Can you give us your impressions on Trodelvy’ Risk of Death reduction by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study? Median PFS extended to 4.8 months from 1.7 months with chemotherapy, trodelvy also extended median overall survival to 11.8 months vs. 6.9 months.

Added By: slingshot_insights
Q4.

Can you share with us any first hand or second hand impressions of using Trodelvy, since its approval in triple negative breast cancer in april 2020?

Added By: slingshot_insights
Q5.

Is Trodelvy regarded as standard therapy for patients with pretreated metastatic triple-negative breast cancer now?

Added By: slingshot_insights
Q6.

In previously treated hormone receptor-positive/HER2-negative metastatic breast cancer, Trodelvy showed, at a median follow-up of 11.5 months, ORR of 31.5% [19.5%-45.6%; 17 partial responses]; median DOR of 8.7 months, median PFS of 5.5 months, and median OS of 12 months. Can you comment on these results?

Added By: slingshot_insights
Q7.

How likely would you be to use Trodelvy in the future, in eventuality of an FDA approval for HER2 negative metastatic breast cancer?

Added By: slingshot_insights

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.